FCGR3A and lymphoma: AFM13 (CD16/CD30) is the first-in-class tetravalent bispecific molecule targeting CD30-positive lymphoma, and has shown promising antitumor responses in recent clinical trials when used as a monotherapy as well as in combination with allogenic NK cells (116, 117).